News
Partnership sets out to improve AI-driven pregnancy support
The innovation arm of the Middle East’s largest medical centre has teamed up with a femtech firm to develop better AI-driven pregnancy monitoring technology.
ARC, the global health innovation engine and transformation arm of Sheba Medical Center, has announced a collaboration with remote pregnancy monitoring medtech Nuvo.
Their aim is to co-develop AI solutions that improve clinical decision-making and early detection of pregnancy complications.
Nuvo’s remote monitoring tech enables expectant mothers to track their pregnancy from home.
The collaboration will be led by Dr. Avi Tsur, an OB/GYN and high-risk pregnancy expert, and director of the Women’s Health Innovation Center at Sheba Beyond, Sheba’s virtual hospital.
From its base in Israel, Sheba aims to become one of the world’s first fully-integrated AI hospitals. It has other collaborations with top institutions like the Mayo Clinic in its work to integrate AI across departments.
Laurence Klein, CEO of Nuvo, said: “We are excited to embark on this collaborative commercial and research partnership with Sheba’s ARC, predicated on innovative, AI-driven modules powered by the INVU platform. ARC and Sheba Beyond’s global leadership in advancing remote and hybrid pregnancy care is invaluable, and we look forward to driving meaningful transformation together.”
Prof. Eyal Zimlichman, chief transformation and innovation officer and sirector of ARC at Sheba Medical Center, said: “Our partnership with Nuvo represents the future of pregnancy care. Integrating AI-powered solutions into routine prenatal monitoring not only enhances pregnancy outcomes but also demonstrates how technology can revolutionize healthcare worldwide.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






